Pharmacologic management of obesity: Updates on approved medications, indications and risks.
Camille Lupianez-MerlySaam DilmaghaniKia VosoughiMichael CamilleriPublished in: Alimentary pharmacology & therapeutics (2024)
AOMs have established efficacy and effectiveness for weight loss even beyond 52 weeks. Further pharmacological options, such as dual and triple incretins, are probable forthcoming additions to clinical practice for combating obesity and its metabolic consequences such as metabolic dysfunction-associated steatotic liver disease.
Keyphrases
- weight loss
- bariatric surgery
- clinical practice
- insulin resistance
- roux en y gastric bypass
- metabolic syndrome
- gastric bypass
- weight gain
- type diabetes
- high fat diet induced
- randomized controlled trial
- oxidative stress
- glycemic control
- human health
- obese patients
- body mass index
- gestational age
- physical activity
- skeletal muscle
- drug administration
- preterm birth